Reyon Pharmaceutical to Repurchase KRW 3 Billion of Debt Before Maturity

• Reyon Pharmaceutical will repurchase KRW 3 billion face value of third-series convertible bonds before maturity on Nov. 2, 2026.
• The KRW 3.32 billion payment covers principal and interest, funded with internal cash through an over-the-counter purchase.
• Outstanding bond principal will fall to KRW 80.95 billion; the bonds mature Oct. 25, 2029.
• The board will determine the repurchased bonds’ subsequent treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reyon Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102000288), on November 02, 2026, and is solely responsible for the information contained therein.